𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Refractory autoimmune thrombocytopenic purpura treatment with Rituximab

✍ Scribed by Kashyap Patel; Jessica Berman; Andres Ferber; Jaime Caro

Publisher
John Wiley and Sons
Year
2001
Tongue
English
Weight
49 KB
Volume
67
Category
Article
ISSN
0361-8609

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Rituximab for treatment of refractory/re
Rituximab for treatment of refractory/relapsing thrombotic thrombocytopenic purpura (TTP)
✍ Afaq Ahmad; Anita Aggarwal; Daya Sharma; Harish P. Dave; Virginia Kinsella; Marg πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 112 KB πŸ‘ 2 views

## Abstract Plasma exchange is the standard treatment for thrombotic thrombocytopenic purpura (TTP). For patients refractory to plasma exchange, treatment options are limited and often unsuccessful. The platelet thrombi that form in acquired TTP are believed to result from the presence of procoagul

Efficiency of rituximab in the treatment
Efficiency of rituximab in the treatment of autoimmune thrombocytopenic purpura associated with common variable immunodeficiency
✍ M. MahΓ©vas; L. Le Page; V. Salle; R. Cevallos; A. Smail; P. Duhaut; J.P. Ducroix πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 205 KB πŸ‘ 2 views

## Unusual Behavior of Primary Tonsillary Lymphoma To the Editor: Primary tonsillary lymphoma accounts for less than 1% of head and neck malignancies. Tonsillectomy is used to mainly establish the diagnosis and can be performed for localized small lesions. In general, the patients are treated by c

Rituximab for the treatment of refractor
Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): Report of three cases
✍ Lydia Koulova; Doru Alexandrescu; Janice P. Dutcher; Kevin P. O'Boyle; Saji Eape πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 162 KB πŸ‘ 2 views

Three patients (one with idiopathic thrombocytopenic purpura [ITP] and two with thrombotic thrombocytopenic purpura [TTP]) were treated with rituximab (anti-CD20 chimeric antibody) at a dose of 325 mg/m 2 administered weekly after they failed standard therapies. The patient with ITP who did not resp